《神州民企》君實生物（１８７７）醫實體瘤產品申臨床試驗獲受理

　　《經濟通通訊社９日專訊》君實生物（０１８７７）（滬：６８８１８０）公布，注射用
ＪＳ２１２獲得國家藥品監督管理局核准簽發的受理通知書，藥物臨床試驗申請獲受理。
　
　　該集團指，ＪＳ２１２是重組人源化抗表皮生長因子受體和人表皮生長因子受體３雙特異性
抗體偶聯藥物，主要用於晚期惡性實體瘤的治療。（ｗｈ）

【你點睇？】TikTok美國禁令生效前大批「TikTok難民」湧入小紅書，你認為該現象會否對中美文化交流帶來正面影響？特朗普暫緩禁令後小紅書熱潮會否持續？► 立即投票

返回全日新聞

回頁頂

經濟通
強化版MQ
強化版TQ
財曆
Mobile
Web

客務熱線︰(852) 2880 7004 客務郵箱︰cs@etnet.com.hk
關於我們 | 產品服務 | 廣告查詢 | 聯絡我們 | 私隱政策 | 使用條款 | 網站導航 | 有用連結 | RSS新聞

Copyright 2025 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.

《經濟通》所刊的署名及／或不署名文章，相關內容屬作者個人意見，並不代表《經濟通》立場，《經濟通》所扮演的角色是提供一個自由言論平台。